Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 46% p.a., Reaching $8.6B by 2027 – Market Report by DeciBio Consulting LLC
10/19/2022 - 09:30 AM
LOS ANGELES --(BUSINESS WIRE)--
According to a comprehensive market report authored by DeciBio Consulting LLC , “Oncology Liquid Biopsy (LBx) Market Report 2022 - 2027 ,” the global oncology liquid biopsy market, driven by growth in new applications – primarily minimum residual disease (MRD) testing, serial monitoring, and early cancer detection – is predicted to reach $8.6B
This second edition of DeciBio’s liquid biopsy report takes an updated and comprehensive look at the liquid biopsy (LBx) landscape. Informed by a combination of primary research, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of the key LBx market segments.
Historically, liquid biopsies have largely been used for genomic profiling and therapy selection. However, now, liquid biopsies are finding new applications throughout the patient journey and within pharma research.
Compared to tissue samples, liquid biopsies are less invasive, faster to process, and a more effective tool for biomarker testing, especially when tissue is unavailable and/or when serial testing is desired. Liquid biopsies can be used to detect the earliest signs of cancer – supplementing existing screening methods and providing a new screening option for many cancers without any screening protocols. Liquid biopsies are experiencing a rapid uptake in oncology care, driven by technological advancements and increased clinical validation. And further growth lies ahead.
Report Methodology / Scope:
Report Details
Research Methods
Secondary research: analysis of >380 LBx-related congress abstracts published since 2020, review of earnings reports and investor calls, review of company websites and publications, identification and characterization of LBx clinical trials
Primary research: interviews with 36 oncology stakeholders — including clinical personnel (e.g., oncologists, pathologists, primary care clinicians) and industry personnel (e.g., biopharma researchers, diagnostic industry veterans) from the U.S. , Europe , and Asia-Pacific (APAC)
Market analysis: 4 independent market models, including a mix of top-down and bottom-up approaches
2027 Market size
$8.6 billion
CAGR (2022 – 2027)
46%
Base Year
2022 (current)
Forecast Period
2022-2027
Market / Forecast Currency
USD
Report Coverage
Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis; quotes from clinical and research stakeholders
Segments Covered
Application (early cancer detection, therapy selection, MRD, monitoring / surveillance, pharma trials, and research)
Geography (U.S. , Europe , APAC, ROW)
Tumor type (lung cancer, breast cancer, colorectal cancer, prostate cancer, others)
Business model (kits, services)
Competitor groups
Learn more about DeciBio’s Oncology Liquid Biopsy (LBx) Market Report 2022 - 2027 here: https://www.decibio.com/market-reports/global-oncology-liquid-biopsy-manufacturing-market-report
Liquid Biopsy Companies Mentioned :
Adela
AmoyDx
Berry Oncology
Biological Dynamics
Burning Rock Biotech
C2i Genomics
Caris Life Sciences
DELFI Diagnostics
Exact Sciences
Epigenomics AG
Foresight Diagnostics
Foundation Medicine
Freenome
Geneseeq Technology Inc.
Genetron Holdings
GRAIL
Guardant Health
Illumina
Invitae (ArcherDx )
LabCorp / PGDx
Tempus
Thermo Fisher Scientific
Natera
NeoGenomics (Inivata )
Personalis
Predicine
Roche
SeekIn
Singlera Genomics
Strata Oncology
Liquid Biopsy Market Analysis:
Market Drivers
The increased clinical utility, commercial availability, regulatory approval, and (initial) reimbursement of blood-based MRD/monitoring and EDx assays will drive market growth – with the U.S. leading the way in novel applications like monitoring and early detection. Increased access to and development of targeted therapeutics, especially ex-U.S. , will lead to increased biomarker testing. This will put further demand on limited tissue samples, driving demand for LBx testing. Lastly, the availability of comprehensive “next-gen” LBx assays (e.g., those with WES/WTS, methylation analysis, etc.) will enable more advanced translational research and biomarker discovery efforts in pharma.
Market Moderators
Regulators, payors, and clinicians still consider tissue sampling as the gold standard for biomarker testing. Thus, there will need to be sufficient evidence to approve, cover, and adopt LBx into routine care. Although LBx developers are continuously generating such evidence, changing the status quo takes time. For example, large and lengthy clinical trials with subsequent outcomes data are needed to prove the value of LBx in many applications. Lack of access to precision therapies in certain geographies moderates the need for liquid biopsy testing today. The adoption of LBx for therapy selection is potentially impacted in instances where tissue sampling is more readily available and there is a push for targeted therapies in earlier stages. The price of LBx for therapy selection will experience pressure as competition increases.
About DeciBio:
DeciBio Consulting (www.decibio.com ) is the leading strategy consulting, market intelligence, and SaaS firm dedicated to accelerating the adoption and impact of technologies enabling precision medicine.
Headquartered in Los Angeles, California , DeciBio serves a global base of clients and customers, ranging from startups to Fortune 500 healthcare corporations. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, voice-of-customer feedback, technology assessment, and commercial due diligence.
View source version on businesswire.com : https://www.businesswire.com/news/home/20221019005181/en/
Rebecca Burnham
becca.burnham@decibio.com
Source: DeciBio Consulting LLC
Genetron Holdings Ltd
NASDAQ:GTH
GTH Rankings
#485 Ranked by Stock Gains
GTH Stock Data
Industry
Medical Laboratories
Sector
Health Care and Social Assistance
Tags
Health Services, Medical/Nursing Services, Health Care and Social Assistance, Medical Laboratories
About GTH
genetron holdings limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. the company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as hccscreen, a proprietary assay for the early screening of liver cancer. it also provides in-vitro diagnostics products, including 8-gene lung cancer assay, an ivd assay product based on semiconductor sequencing to detect lung cancer; genetron 3d biochip reading instrument; idh1/tert gene assays for glioma; genetron s5, a semiconductor sequencer used in the field of gene detection; and genetron s2000 that enables gene panel sequencing. in addition, the company develops ctdna lung cancer assay for mutations in the epidermal growth factor receptor gene. it also offers development services in the areas of genomics research and clinical development in collabor
